tissue plasminogen activato
Clinical Outcomes of Endovascular Thrombectomy in Tissue Plasminogen Activator versus Non-Tissue Plasminogen Activator Patients at Primary Stroke Care Centers.
... intravenous tissue plasminogen activator (IV tPA) administration before endovascular intervention as compared to without at thrombectomy‑capable low‑volume centers on procedural aspects and patient outcomes ...
5
Structural and kinetic comparison of recombinant human single and two chain tissue plasminogen activator
... single-chain tissue plasminogen activator (sct-PA) and two-chain tissue plasminogen activator (tct-PA), and compared these structural data with measurement of enzymatic ...
8
Enzymatic vitreolysis with recombinant tissue plasminogen activator for vitreomacular traction
... Keywords: tissue plasminogen activator (rTPA), vitreous body, macular hole, vitrectomy, epiretinal membrane, diabetic retinopathy.. Introduction.[r] ...
10
The regulation of tissue plasminogen activator in rat brain glioma cells
... The m urine tPA gene can also be expressed in a tissue specific m anner (P eco rin o et al., 1991). T hese w o rk ers used an i n v i t r o assay to in v estig ate the effects o f m urine brain, kid n ey and liv ...
212
Tissue plasminogen activator promotes platelet disaggregation in plasma
... We studied the disaggregation of human platelets by tissue-type plasminogen activator (t- PA). When added to a suspension of human platelets induced to aggregate in plasma with adenosine 5'-diphosphate, ...
8
Binding of tissue plasminogen activator to cultured human endothelial cells
... involving binding sites of both high (Kd, 28.7 +/- 10.8 pM; Bmax, 3,700 +/- 300) and low (Kd, 18.1 +/- 3.8 nM; Bmax 815,000 +/- 146,000) affinity. t-PA binding was 70% inhibited by a 100-fold molar excess of u-PA. When ...
9
GLP-1 RECEPTOR ACTIVATION-BASED THERAPY; A PROMISING STRATEGY AGAINST ISCHEMIC STROKE
... recombinant tissue plasminogen activator (rtpa) treatment in animal models of ischemic stroke (28, 29), The correlation between hyperglycemia and aggravated cerebral injury in stroke yielding a poor ...
6
Fibrinolysis regulation by platelets retaining plasminogen and tissue-type plasminogen activator on their surface
... lets compared with 5.02 ± 0.7 for control), which to- gether indicates stimulation of fibrinolysis by plate- lets. It should also be noted that in the presence of platelets, fibrin polymerization was accompanied by an ...
11
Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy
... Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration. Pneumatic displacement of[r] ...
8
Central serous chorioretinopathy: a pathogenetic model
... Abstract: Despite numerous studies describing predominantly its demography and clinical course, many aspects of central serous chorioretinopathy (CSCR) remain unclear. Perhaps the major impediment to finding an effective ...
5
Tissue type plasminogen activator induces opening of the blood brain barrier via the LDL receptor–related protein
... Temporal and spatial relationship between tPA activity and vascular permeability following MCAO in WT (C57BL/6J) mice. In a–d, tPA activ- ity 1 hour after MCAO is shown in red by in situ zymography, and cell nuclei are ...
9
Tissue type plasminogen activator is a neuroprotectant in the mouse hippocampus
... The best-known function of the serine protease tissue-type plasminogen activator (tPA) is as a thrombolytic enzyme. However, it is also found in structures of the brain that are highly vulnerable to ...
13
Influence of the fast acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue type plasminogen activator in rabbits Interference of tissue derived components
... of plasminogen activator (PA-inhibitor) on thrombolysis was investigated in rabbits with a jugular vein ...human tissue-type plasminogen activator (t-PA) produced similar degrees of thrombolysis in ...
8
Localization of the binding site of tissue type plasminogen activator to fibrin
... of tissue-type plasminogen ...two-chain tissue-type plasminogen activator, however, destroyed both the binding and catalytic ...of tissue-type plasminogen activator that ...
8
Effect of urokinase antiserum on plasminogen activators: demonstration of immunologic dissimilarity between plasma plasminogen activator and urokinase
... detectable levels of urokinase activity in peripheral venous or renal venous blood under a variety of clinical states and when stimuli such as exercise, electroshock therapy, or nicotinic acid were used to enhance ...
17
Management of Plastic Bronchitis With Topical Tissue-type Plasminogen Activator
... Plastic bronchitis or cast bronchitis is a rare disease of unclear etiology characterized by formation of airway casts that can lead to life- threatening airway obstruction. There is currently limited data regard- ing ...
7
Sites of synthesis of urokinase and tissue type plasminogen activators in the murine kidney
... of plasminogen activators ...on tissue sections and in situ hybridizations, we have explored the cellular distribution of urokinase-type (u-PA) and tissue-type (t-PA) plasminogen activators ...
10
Tissue-Type Plasminogen Activator, Plasminogen Activator Inhibitor, and Histidine-Rich Glycoproteins in Stressed Human Newborns
... Tissue-type plasminogen activator antigen was determined by an enzyme-linked immuno- sorbent assay (ELISA) method using a commercial kit (Imubind-5- tPA, American Diagnostica).4’9 Plasmi[r] ...
6
alpha Fucose mediated binding and degradation of tissue type plasminogen activator by HepG2 cells
... Binding and degradation of tissue-type plasminogen activator by the human hepatoma cell line HepG2.. Interactions between tissue-type plasminogen activator and extracellular matrix assoc[r] ...
9
Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease
... suPAR, tissue inhibitor of metalloproteinase-1 (TIMP-1), Matrix metalloproteinase-9 (MMP-9), and C-reactive protein (CRP) were detected with Magnetic Luminex Screening ...
8